

12 January 2026

Diagnosis of Alzheimer’s Disease

1. Where, if at all, does the Trust carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s disease?

	Yes / No
Lumbar punctures carried out within the Trust itself	Yes
Lumbar punctures referred elsewhere and carried out external to the Trust	No
Trust does not carry out lumbar punctures to diagnose Alzheimer’s Disease	No

2. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar punctures in the diagnosis of Alzheimer’s disease.

Full name of organisation(s)
No – as the answer above is no

3. How many lumbar punctures to test for Alzheimer’s disease took place in the last three-month period for which data are available?

	Number of procedures
Number of lumbar punctures	20

4. How many blood-based biomarker (BBBM) tests for Alzheimer’s disease were conducted during the last three-month period?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of Blood-based Biomarker tests	0	0	0

12 January 2026

5. Where, if at all, does the Trust carry out Blood-based Biomarker (BBBM) tests for diagnosing NHS patients with Alzheimer's disease?

	Yes / No
Pathology laboratory within the Trust	No
Pathology laboratory external to the Trust	No
Trust does not test for BBBMs to diagnose Alzheimer's Disease	No

6. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood-based Biomarker tests for the diagnosis of Alzheimer's disease for NHS patients.

Full name of Trust or organisation(s)
No as the answer above is no

7. Which biomarker tests are used to detect Alzheimer's disease for patients in the care of the Trust, whether the BBBM tests are carried out within or outside of the Trust?

Full name of biomarker tests
No blood-based dementia biomarkers currently tested in Trust

8. How many pTau181 immunoassay tests were conducted to test for Alzheimer's disease in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau181 tests	BBM - 0		

12 January 2026

9. Is pTau181 testing for Alzheimer’s disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau181 Testing associated with clinical trial activity	BBM - 0

10. How many pTau181 immunoassay tests were conducted for Alzheimer's disease as part of a clinical trial?

Number of pTau181 tests	BBM - 0
-------------------------	---------

11. How many pTau217 immunoassay tests were conducted to test for Alzheimer's disease in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau217 tests	BBM - 0		

12. Is pTau217 testing for Alzheimer ’s disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	No

12 January 2026

13. How many pTau217 immunoassay tests were conducted for Alzheimer's disease as part of a clinical trial?

Number of pTau217 tests	BBM - 0
-------------------------	---------

14. Does your organisation participate in any of the following clinical trials?

	Yes / No
READ-OUT	Yes
ADAPT	Not as a centre
Other(s) please specify below:	

15a. Which of the following metrics are used by the Trust to measure Blood-based Biomarker (BBBM) in the diagnosis of Alzheimer's Disease?

Belfast Trust do not use BBBM in the diagnosis of Alzheimer's Disease.	Yes / No
Number of tests	No
Number of kits	No
Number of runs	No
Number of units	No
Number of patients	No

12 January 2026

15b. Please can you help us understand how your centre defines the following:

Belfast Trust do not use BBM in the diagnosis of Alzheimer's Disease.

Metrics	Definition
Number of tests	N/A
Number of kits	N/A
Number of runs	N/A
Number of units	N/A